Topotecan
Active ingredient: Topotecan
In short: Topotecan Injection is indicated for the treatment of: small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 da
What is Topotecan used for?
Topotecan Injection is indicated for the treatment of:
small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy
.
Topotecan Injection in combination with cisplatin is indicated for the treatment of:
stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.
âš Boxed warning (FDA's strongest warning)
Do not give Topotecan Injection to patients with baseline neutrophil counts less than 1,500 cells/mm
3
. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection and death, monitor peripheral blood counts frequently on all patients receiving Topotecan Injection.
Topotecan dosage
Verify dose using body surface area prior to dispensing. Recommended dosage should not exceed 4 mg .
Prior to administration of the first course of Topotecan Injection, patients must have a baseline neutrophil count of >1,500 cells/mm
3and a platelet count of >100,000 cells/mm
3.
Recommended Dosage
The recommended dose of topotecan is 1.5 mg/m
2by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on day 1 of a 21-day course.
In the absence of tumor progression, a minimum of 4 courses is recommended because tumor response may be delayed. The median time to response in 4 small cell lung cancer trials was 5 to 7 weeks.
Dosage Modification Guidelines
In the event of severe neutropenia (defined as <500 cells/mm
3) during any course, reduce the dose by 0.25 mg/m
2(to 1.25 mg/m
2) for subsequent courses.
Alternatively, in the event of severe neutropenia, administer G-CSF (granulocyte-colony stimulating factor) following the subsequent course (before resorting to dose reduction) starting from day 6 of the course (24 hours after completion of topotecan administration).
In the event the platelet count falls below 25,000 cells/mm
3, reduce doses by 0.25 mg/m
2(to 1.25 mg/m
2) for subsequent courses.
Recommended Dosage
The recommended dose of Topotecan Injection is 0.75 mg/m
2by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m
2by intravenous infusion on day 1 repeated every 21 days (a 21-day course).
Dosage Modification Guidelines
Dosage adjustments for subsequent courses of Topotecan Injection in combination with cisplatin are specific for each drug. See manufacturer’s prescribing information for cisplatin administration and hydration guidelines and for cisplatin dosage adjustment in the event of hematologic toxicity
In the event of severe febrile neutropenia (defined as <1000 cells/mm
3with temperature of 38°C or 100.4°F), reduce the dose of Topotecan Injection to 0.60 mg/m
2for subsequent courses.
Alternatively, in the event of severe febrile neutropenia, administer G-CSF following the subsequent course (before resorting to dose reduction) starting from day 4 of the course (24 hours after completion of administration of Topotecan Injection).
If febrile neutropenia occurs despite the use of G-CSF, reduce the dose of Topotecan Injection to 0.45 mg/m
2for subsequent courses.
In the event the platelet count falls below 25,000 cells/mm
3, reduce doses to 0.60 mg/m
2for subsequent courses.
Renal Impairment
No dosage adjustment of Topotecan Injection appears to be required for patients with mild renal impairment (Cl
cr40 to 60 mL/min.). Dosage adjustment of Topotecan Injection to 0.75 mg/m
2is recommended for patients with moderate renal impairment (20 to 39 mL/min.). …
How to take Topotecan — instructions & advice from the label
Inform patients that Topotecan Injection decreases blood cell counts such as white blood cells, platelets, and red blood cells. Patients who develop fever, other signs of infection (e.g., chills, cough, or burning pain on urination), or bleeding while on therapy should notify their physician promptly. Inform patients that frequent blood tests will be performed while taking Topotecan Injection to monitor for the occurrence of bone marrow suppression.
Advise patients to use effective contraceptive measures to prevent pregnancy and to avoid breastfeeding during treatment with Topotecan Injection.
Inform patients that Topotecan Injection may cause asthenia or fatigue. If these symptoms occur, caution should be observed when driving or operating machinery.
Rx only
Manufactured for:
Accord Healthcare, Inc.,
8041 Arco Corporate Drive,
Suite 200,
Raleigh, NC 27617,
USA.
Manufactured by:
Intas Pharmaceuticals Limited,
Plot No.: 457, 458, Village – Matoda,
Bavla Road, Ta.- Sanand,
Dist.- Ahmedabad – 382 210,
INDIA.
10 7121 0 6027367
Issued December 2023
Warnings & precautions
Do not take this medicine if: Topotecan Injection is contraindicated in patients who have a history of severe hypersensitivity reactions (e.g., anaphylactoid reactions) to topotecan or to any of its ingredients. Topotecan Injection should not be used in patients with severe bone marrow depression.
Bone marrow suppression (primarily neutropenia) is the dose-limiting toxicity of Topotecan Injection. Neutropenia is not cumulative over time. In the comparative study, in small cell lung cancer, the treatment-related death rates were 5% for topotecan and 4% for CAV (cyclophosphamide-doxorubicin-vincristine).
Neutropenia
From a combined experience of patients receiving topotecan which included patients treated for small cell lung cancer: Grade 4 neutropenia (<500 cells/mm
3) was most common during course 1 of treatment (60% of patients) and occurred in 39% of all courses, with a median duration of 7 days. The nadir neutrophil count occurred at a median of 12 days. Therapy-related sepsis or febrile neutropenia occurred in 23% of patients, and sepsis was fatal in 1%. Pancytopenia has been reported.
Cervical cancer experience: Grade 3 and grade 4 neutropenia affected 26 % and 48 % of patients, respectively.
Thrombocytopenia
From a combined experience of patients receiving topotecan which included patients treated for small cell lung cancer: Grade 4 thrombocytopenia (<25,000/mm
3) occurred in 27% of patients and in 9% of courses, with a median duration of 5 days and platelet nadir at a median of 15 days. Platelet transfusions were given to 15% of patients in 4% of courses.
Cervical cancer experience: Grade 3 and grade 4 thrombocytopenia affected 26 % and 7 % of patients, respectively. …
Topotecan side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Small Cell Lung Cancer
Data in the following section are based on the combined experiences of the 879 patients studied, including 426 patients with small cell lung cancer treated with topotecan.
Table 1
lists the principle hematologic adverse reactions and
Table 2
lists non-hematologic adverse reactions occurring in at least 15% of patients.
Hematologic Adverse Reaction | Patients
(n=879)% Incidence
Neutropenia
<1,500 cells/mm
3
<500 cells/mm
3 | 9778
Leukopenia
<3,000 cells/mm
3
<1,000 cells/mm
3 | 9732
Thrombocytopenia
<75,000/mm
3
<25,000/mm
3 | 6927
Anemia
<10 g/dL<8 g/dL | 8937
Non-hematologic
Adverse Reaction | Percentage of Patients with Adverse Reaction (879 Patients)
All Grades | Grade 3 | Grade 4
Infections and infestations
Sepsis or pyrexia/infection with neutropenia
a | 43 | NR | 23
Metabolism and nutrition disorders
Anorexia | 19 | 2 | <1
Nervous system disorders
Headache | 18 | 1 | <1
Respiratory, thoracic, and mediastinal disorders
Dyspnea | 22 | 5 | 3
Coughing | 15 | 1 | 0
Gastrointestinal disorders
Nausea | 64 | 7 | 1
Vomiting | 45 | 4 | 1
Diarrhea | 32 | 3 | 1
Constipation | 29 | 2 | 1
Abdominal pain | 22 | 2 | 2
Stomatitis | 18 | 1 | <1
Skin and subcutaneous tissue disorders
Alopecia | 49 | NA | …
Drug interactions
G-CSF:
Concomitant administration of G-CSF can prolong the duration of neutropenia, so if G-CSF is to be used, do not initiate it until day 6 of the course of therapy, 24 hours after completion of treatment with Topotecan Injection.
Platinum and Other Cytotoxic Agents:
Myelosuppression was more severe when topotecan, at a dose of 1.25 mg/m
2/day for 5 days, was given in combination with cisplatin at a dose of 50 mg/m
2in Phase 1 studies. In one study, 1 of 3 patients had severe neutropenia for 12 days and a second patient died with neutropenic sepsis.
Greater myelosuppression is also likely to be seen when Topotecan Injection is used in combination with other cytotoxic agents, thereby necessitating a dose reduction. However, when combining topotecan with platinum agents (e.g., cisplatin or carboplatin), a distinct sequence-dependent interaction on myelosuppression has been reported. Coadministration of a platinum agent on day 1 of dosing with topotecan required lower doses of each agent compared to co-administration on day 5 of the dosing schedule for topotecan. …
About this medicine
Topotecan is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitory activity.
The chemical name for topotecan free base is (
S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1
H-pyrano[3’,4’:6,7]indolizino[1,2-
b]quinoline-3,14-(4
H,12
H)-dione. It has the molecular formula C
23H
23N
3O
5and a molecular weight of 421.45.
Topotecan has three pKa values: pKa
1= 10.50 corresponding to the benzyldimethylamino group, pKa
2= 6.99 corresponding to the phenol group and pKa
3= 0.60 corresponding to the quinoline group.
As formulated in Topotecan Injection, topotecan has the following structural formula:
where n is >1, corresponding to HCl added to adjust the pH to approximately 1.5 to 2.5.
Topotecan Injection is supplied as a sterile, non-pyrogenic, clear, yellow solution at a topotecan free base concentration of 4 mg/4 mL (1 mg/mL) and 1 mg/mL available in multiple dose vials. Each mL of Topotecan Injection contains topotecan hydrochloride equivalent to 1 mg of topotecan as free base, 5 mg tartaric acid, NF, and water for injection, USP. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7636bc1e-77b6-46ad-9df0-c8bb1c5e503f. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate